0000000000959428

AUTHOR

Paolo Pronzato

showing 3 related works from this author

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times

2020

I have been very much impressed by the clarity, pragmatism and good medical judgement of the article by Camilo Porta,1 a respected and dedicated ESMO faculty member and friend, giving his personal perspective on real issues many oncologists working in a public system are eventually facing during the SARS-CoV-2 pandemic. I understand Professor Porta is voicing what many oncologists from countries deeply affected by the pandemic, such as Italy or Spain, may think. Although I concur with most of his approaches and comments, I would like to complement some of these statements with some additional thoughts. Medicine was created more than 2500 years ago as a profession aiming at alleviating suffe…

PragmatismCancer Researchbusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)media_common.quotation_subjectPerspective (graphical)JudgementFace (sociological concept)Public relationslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282law.inventionOncologylawPolitical sciencePandemicCLARITYbusinessmedia_commonHealthcare systemESMO Open
researchProduct

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results …

2010

This study evaluated the effects of epoetin alfa on patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy. Early intervention with epoetin alfa was well tolerated and improved anemia-related patient-reported outcomes.

AdultCancer Researchmedicine.medical_specialtySurvivalAnemiaPopulationAntineoplastic AgentsBreast NeoplasmsAcademia–Pharma Intersectlaw.inventionbreast cancer; anemia; erythropoietin; hemoglobin; survival; fatigueHemoglobinsBreast cancerRandomized controlled trialstomatognathic systemlawInternal medicinehemic and lymphatic diseasesBreast CancermedicineClinical endpointHumansBlood TransfusionHemoglobinProspective StudieseducationSurvival rateErythropoietinFatigueAgededucation.field_of_studybusiness.industryEpoetin alfavirus diseasesAnemiaMiddle Agedmedicine.diseasedigestive system diseasesRecombinant ProteinsSurgeryEpoetin AlfaOncologyErythropoietinHematinicsFemalebusinesstherapeuticsmedicine.drug
researchProduct